Fondaparinux Market to reach $1,459.5 million by 2035

Fondaparinux market was valued at approximately $778.4 million in 2025 and is projected to reach around $1,459.5 million by 2035, expanding at a CAGR of 6.6% during the forecast period from 2026 to 2035. Market growth is primarily driven by the rising burden of thromboembolic disorders and increasing demand for effective anticoagulant therapies. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 17.9 million casualties annually, with thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) being major contributors. This growing disease burden is significantly increasing the adoption of anticoagulants like fondaparinux, particularly in hospital settings for surgical thromboprophylaxis and acute care management.

Browse the full report description of “Fondaparinux Market Size, Share & Trends Analysis Report by Product Type (Branded and Generics), by Application (Deep Vein Thrombosis, Pulmonary Embolism, Acute Coronary Syndrome, Post-Surgical Thromboprophylaxis), by End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/fondaparinux-market

Innovation Leaders Transforming the Fondaparinux Market

The key players in the fondaparinux market include top companies such as Teva Pharmaceutical, Viatris, Sandoz, Fresenius Kabi, and Dr. Reddy’s Laboratories, among others. The market is witnessing steady growth due to the increasing prevalence of venous thromboembolism (VTE) and the rising number of surgical procedures globally. Hospitals remain the primary end-users, accounting for the majority of product utilization due to inpatient anticoagulant administration. Additionally, the growing adoption of targeted anticoagulants and improved clinical guidelines for thrombosis management are supporting market expansion.

• In December 2024, the US FDA approved Arixtra (fondaparinux) for treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year and older weighing at least 10 kg. This broadened the product’s patient base beyond adults and created a new growth avenue in pediatric anticoagulation therapy.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Product Type
• By Application
• By End-User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Teva Pharmaceutical, Viatris, Sandoz, Fresenius Kabi, Dr. Reddy’s Laboratories, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Fondaparinux Market Report Segment

By Product Type

• Branded
• Generics

By Application

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Acute Coronary Syndrome (ACS)
• Post-Surgical Thromboprophylaxis

By End-User

• Hospitals
• Specialty Clinics (Cardiology / Vascular centers)
• Ambulatory Surgical Centers (ASCs)

Global Fondaparinux Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/fondaparinux-market